EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis

Meghana Sathe, Steven D Freedman, Melissa S Putman, Robert Gallotto, Marcie Clarkin, Danielle Gallotto, Kateryna Pierzynowska, Drucy Borowitz

Journal of Cystic Fibrosis · 2025-11 · 24 (6) · 1043-1050

DOI: 10.1016/j.jcf.2025.07.008 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cystic Fibrosis, 2025-11. Verfasst von Meghana Sathe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, UTSW/Children's Health, Dallas, TX, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Enzyme Replacement Therapy, Lipase, Exocrine Pancreatic Insufficiency. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic enzyme replacement therapy (PERT) prevents malnutrition in people with exocrine pancreatic insufficiency, including those with cystic fibrosis (CF). We developed a lipase that is stable against proteolysis and at the pH of the fed stomach, so it can be taken during a meal to promote mixing of enzyme and substrate. We designed a dose-ranging study of ANG003, a microbial PERT combining this lipase with low pH-stable protease and amylase, also of microbial origin. METHODS: This was a multicenter, randomized evaluation of ANG003 in subjects with CF, studied once without PERT and again after randomization to a single dose level of four possible combinations of lipase, protease, and amylase. We developed blood-based substrate absorption challenge tests employing DHA+EPA, whey and potato starch to determine dose-response to each of these enzymes, respectively. RESULTS: ANG003 improved DHA+EPA absorption with a statistically significant increase with 80 mg and 120 mg lipase doses compared to 20 mg (p = 0.03; p = 0.004). The absorption of total fats followed a similar pattern to DHA+EPA. There was a significant increase in absorbed amino acid equivalents, reflecting proteolysis, over no PERT in the highest (75 mg) dose of protease (p = 0.03). In subjects without diabetes, glucose was slightly lower while c-peptide levels remained unchanged with all amylase doses. Adverse events were mild and transient. No serious adverse events occurred. CONCLUSIONS: ANG003 lipase significantly improves DHA+EPA and total fat absorption in a dose dependent manner. Results for ANG003 protease and amylase activity suggest that doses lower than those in current porcine-derived PERTs may be efficacious.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisEnzyme Replacement TherapyLipaseExocrine Pancreatic InsufficiencyAmylasesPeptide HydrolasesHumansMaleFemaleAdultAdolescentDose-Response Relationship, DrugYoung AdultTreatment Outcome

Stichwörter der Autor:innen

AmylaseCystic fibrosisEnzyme replacement therapyExocrine pancreatic insufficiencyLipaseMalabsorptionProtease

Substanzen

LipaseAmylasesPeptide Hydrolases

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology and Nutrition, UTSW/Children's Health, Dallas, TX, USA.
  • Beth Israel Deaconess Medical Center, Division of Gastroenterology, Boston, MA (or Beth Israel Deaconess, Division of GI, Boston, MA, USA.
  • Diabetes Research Center, Massachusetts General Hospital, Boston, MA, USA.
  • Anagram Therapeutics, Natick, MA, USA.
  • Anagram Therapeutics, Natick, MA, USA; Department of Biology, Lund University, Lund, Sweden; Department of Animal Physiology, The Kielanowski Institute of Animal Physiology and Nutrition, Jabłonna, Poland; Anara AB, Tre…
  • Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 1001 main Street, 5th Floor, Buffalo, NY 14203, USA. Electronic address: borowitz@buffalo.edu.

Zitieren

APA

Sathe, M., Freedman, S. D., Putman, M. S., Gallotto, R., Clarkin, M., Gallotto, D., Pierzynowska, K., & Borowitz, D. (2025). Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis. Journal of Cystic Fibrosis, 24(6), 1043-1050. https://doi.org/10.1016/j.jcf.2025.07.008

Vancouver

Sathe M, Freedman SD, Putman MS, Gallotto R, Clarkin M, Gallotto D, et al. Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis. Journal of Cystic Fibrosis. 2025;24(6):1043-1050. doi:10.1016/j.jcf.2025.07.008

BibTeX
@article{Sathe2025,
  author = {Sathe, Meghana and Freedman, Steven D and Putman, Melissa S and Gallotto, Robert and Clarkin, Marcie and Gallotto, Danielle and Pierzynowska, Kateryna and Borowitz, Drucy},
  title = {Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {6},
  pages = {1043--1050},
  doi = {10.1016/j.jcf.2025.07.008}
}
Kostenlos starten →